Your browser doesn't support javascript.
loading
Psychometric Properties of Clinical Indicators for Identification and Management of Advanced Parkinson's Disease: Real-World Evidence From G7 Countries.
Antonini, Angelo; Pahwa, Rajesh; Odin, Per; Henriksen, Tove; Soileau, Michael J; Rodriguez-Cruz, Ramon; Isaacson, Stuart H; Merola, Aristide; Lindvall, Susanna; Domingos, Josefa; Alobaidi, Ali; Jalundhwala, Yash J; Kandukuri, Prasanna L; Parra, Juan Carlos; Kukreja, Pavnit K; Onuk, Koray; Bergmann, Lars; Pike, James; Ray Chaudhuri, K.
Afiliação
  • Antonini A; Parkinson and Movement Disorders Unit, Study Centre for Neurodegeneration, Department of Neuroscience, University of Padova, Padova, Italy.
  • Pahwa R; Medical Center, University of Kansas, Kansas, KS, USA.
  • Odin P; University of Lund, Lund, Sweden.
  • Henriksen T; Movement Disorder Clinic, University Hospital of Bispebjerg, Copenhagen, Denmark.
  • Soileau MJ; Texas Movement Disorder Specialists, Georgetown, TX, USA.
  • Rodriguez-Cruz R; Synaptic Precision, Inc, Orlando, FL, USA.
  • Isaacson SH; Parkinson's Disease and Movement Disorders Center, Boca Raton, FL, USA.
  • Merola A; Madden Center for Parkinson Disease and Other Movement Disorders, Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
  • Lindvall S; European Parkinson's Disease Association, Sevenoaks, UK.
  • Domingos J; European Parkinson's Disease Association, Sevenoaks, UK.
  • Alobaidi A; Grupo de Patologia Médica, Nutrição e Exercício Clínico (PaMNEC) do CiiEM, Almada, Portugal.
  • Jalundhwala YJ; AbbVie Inc., North Chicago, IL, USA.
  • Kandukuri PL; University of Illinois at Chicago, Chicago, IL, USA.
  • Parra JC; AbbVie Inc., North Chicago, IL, USA.
  • Kukreja PK; AbbVie Inc., North Chicago, IL, USA.
  • Onuk K; AbbVie Inc., North Chicago, IL, USA.
  • Bergmann L; AbbVie Inc., North Chicago, IL, USA.
  • Pike J; AbbVie Inc., North Chicago, IL, USA.
  • Ray Chaudhuri K; AbbVie Inc., North Chicago, IL, USA.
Neurol Ther ; 11(1): 303-318, 2022 Mar.
Article em En | MEDLINE | ID: mdl-35015215
Advanced Parkinson's disease (PD) refers to the stage of disease when motor complications are difficult to manage with standard therapy. Patients reaching this stage of the disease may benefit from a treatment change from pills to the so-called device-aided therapies. However, there is currently no unanimous definition of advanced PD, which makes it challenging to identify suitable candidates for device-aided therapies. There is urgent need to define specific features (or 'clinical indicators') to support healthcare professionals and patients in the identification of advanced PD as well as to define suitability for device-aided therapy. This study aimed to assess the accuracy of 15 clinical indicators and seven device-aided therapy eligibility criteria using information from a large database of 4714 patients in G7 countries. Physicians classified 14.9% of patients as having advanced PD and 17.5% were judged to be eligible for device-aided therapy. Each clinical indicator or device-aided therapy eligibility indicator was detected more frequently in patients classified as having advanced PD and in patients considered eligible for device-aided therapy, respectively. All indicators had high accuracy for identifying advanced PD and device-aided therapy-eligibility. These previously identified clinical indicators of advanced PD and device-aided therapy eligibility may provide an objective and reliable approach for patient screening and treatment optimization.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Itália